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Background: The World Health Organization (WHO) recently proposed a new definition of se-
vere asthma to facilitate standardized characterization of patients, and enable more accurate
estimations of the prevalence of severe asthma. The aim of this study was to estimate the
prevalence of severe asthma according to the WHO definition in children aged 12 years, in
Stockholm, Sweden.
Methods: The birth cohort BAMSE enrolled 4089 children during 1994e96. Parental question-
naires provided information on asthma-related symptoms, diagnosis and medication from
3015 enrolled children at the age of 12 years. Severe asthma was defined as the presence of
asthma, as well as continuous treatment with inhaled corticosteroids and long-acting beta-2
agonists, based on information from the Swedish prescribed drug register demonstrating pre-
scriptions of at least 800 mg budesonide daily (or equivalent).
Results: The prevalence of asthma was 11% among 12-year-olds (n Z 329). Based on informa-
tion from the Swedish prescribed drug register, seven children with asthma fulfilled the defi-
nition of severe asthma. The estimated prevalence corresponds to 0.23% (95% CI, 0.06e0.4) of
the population, or 2.1% (95% CI, 0.5e3.7) of children with asthma. Based on assessed markers
of asthma control, 3/7 with severe asthma were considered to have controlled asthma and 4/7
had partly or uncontrolled asthma.en Children’s Hospital, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. Tel.:þ46 70 323
ki.se, bjorn.nordlund@karolinska.se (B. Nordlund).
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Prevalence of severe childhood asthma 1235Conclusion: Severe asthma appears rare both among 12-year-old schoolchildren with asthma
and in the general population. Combining self-reported information from a population-based
birth cohort with data from a drug register seems trustworthy in estimating severe asthma
as defined by the WHO.
ª 2014 Elsevier Ltd. All rights reserved.It has been shown that severe childhood asthma causes
extensive restrictions in health-related quality of life [1]. In
a Norwegian birth cohort, severe asthma was found in 0.5%
of all children aged 10 years [2]. No other studies have
recently estimated prevalence of severe childhood asthma.
To facilitate a standardized characterization of patients
that require particular attention, and contribute to an ac-
curate estimate of severe asthma prevalence, the World
Health Organization (WHO) recently proposed a new defi-
nition [3]. The objective was to agree on a common inter-
national approach on evaluation of asthma severity, asthma
control and risk for adverse asthma events. The definition
contains three subtypes with separate health messages: (i)
untreated severe asthma, due to unavailable or unafford-
able treatment, (ii) difficult-to-treat asthma, due to
aggravating factors of e.g. environmental exposures,
comorbidities and poor adherence, and (iii) treatment-
resistant severe asthma. The latter subtype includes
insufficiently controlled asthma despite high-dose treat-
ment with inhaled corticosteroids (ICS), as well as asthma
for which control can be maintained only with high-dose
treatment. To our knowledge, this definition has not been
applied to estimate severe asthma prevalence in a general
paediatric population. The aim of this study was to esti-
mate the prevalence of severe asthma as defined by the
WHO in children aged 12 years in Stockholm, Sweden.
Methods
The BAMSE cohort enrolled 4089 new-born infants from
1994 through 1996 [4]. The children were followed with
parental questionnaires at birth and at 1, 2, 4, 8 and 12
years to obtain information about background factors,
asthma symptoms and medication [5]. The Ethics Commit-
tee at Karolinska Institutet, Stockholm, Sweden, approved
the study and all parents gave informed consent. The study
population consisted of 3015 children prospectively evalu-
ated from birth to 12 years.
Asthma was defined based on the following criteria (at
least two required) [6]; 1) intake of asthma medication due
to asthma symptoms in the last 12 months; 2) history of
wheeze in the same period, and 3) doctor’s diagnosis of
asthma (ever).
Severe asthma was defined as presence of asthma as
defined above, including treatment with continuous ICS and
long-acting beta-2 agonist (LABA), combined with infor-
mation of pharmacy-dispensed prescription of at least
800 mg budesonide daily or equivalent (500 mg flutica-
sone), obtained through the Swedish prescribed drug reg-
ister [3,7,8]. The register lists all prescription drugs
dispensed to Swedish residents since July 2005 [9].Agreement between information from the register and the
12-year follow-up was less than 18 months.
Parental reports of symptoms associated with children’s
asthma control were evaluated 12 months prior to the 12-
year follow-up, and contained features of activity limita-
tion in daily activities, nocturnal asthma, acute healthcare
utilization and wheeze 4 episodes [10,11]. A child’s level
of asthma control was defined as controlled (0 features),
partly controlled (1e2 features) or uncontrolled (3 fea-
tures) [10].
Results
The prevalence of asthma was 11% (n Z 329) among 12-
year-olds. Using the Swedish prescribed drug register,
seven children with asthma and prescribed and dispensed
high-dose treatment of ICS in combination with LABA were
identified as fulfilling the severe asthma definition. The
estimated prevalence at age 12 years corresponds to 0.23%
(95% CI, 0.06e0.4) or 2.1% (95% CI, 0.5e3.7) among children
with asthma. The children with severe asthma are pre-
sented in Table 1. Markers associated with children’s
asthma control were activity limitation (n Z 4), nocturnal
asthma (n Z 3), wheeze 4 episodes (n Z 2) and acute
healthcare utilization (n Z 0).
Discussion
We found a lower but statistically comparable prevalence
(0.23%) to that from a Norwegian study (0.5%) [2], where
each child was clinically assessed including objective
measurements. While our asthma definition has been used
in other epidemiological studies [6,12], a limitation of this
study was that asthma was defined without objectively
evaluating the presence of bronchial hyper-responsiveness.
This could lower the prevalence of asthma and increase the
ratio of severe asthma in our data. However, when we
compare the proportion of severe asthma separately among
the entire study population and asthma cases, no major
difference was observed between our study and the Nor-
wegian study [2]. Further, Lang et al. concluded that
spirometric measurements are insensitive discriminators of
problematic severe asthma in childhood [13]. We consider
the combined use of data from the drug register and birth
cohort trustworthy in identifying children with severe
asthma. One strength of our study was detailed information
about pharmacy-dispensed asthma medication. However,
children’s asthma treatment could change up to high-dose
ICS-level without prescription or dispensing of new medi-
cation, which is a limitation.









Rhinitisc Controller treatment (daily dose) LTRAd Asthma controle
1 F 13.4   þ Budesonide 800 mg/Formoterol 18 mg  Partly controlled
2 M 13.4 þ  þ Fluticasone 500 mg/Salmeterol 200 mg  Controlled
3 M 13.2  þ þ Budesonide 800 mg/Formoterol 18 mg þ Uncontrolled
4 M 12.4 þ þ þ Fluticasone 500 mg/Salmeterol 200 mg  Uncontrolled
5 M 12.1 þ þ  Fluticasone 500 mg/Salmeterol 200 mg  Controlled
6 F 12.0    Fluticasone 500 mg/Salmeterol 200 mg  Controlled
7 F 12.0  þ þ Fluticasone 500 mg/Salmeterol 200 mg  Partly controlled
a Heredity for atopy emother and/or father with doctor’s diagnosis of asthma and medication and/or doctor’s diagnosis of hay fever in
combination with furred pet and/or pollen allergy at the time of birth.
b Body mass index adjusted for sex and age at 12-year follow-up.
c Symptoms of prolonged sneezing or runny or blocked nose without common cold in the last 12 months.
d Treatment with leukotriene antagonist last 12 months prior to follow-up.
e Based on parental information 12 months prior to assessment, including four characteristics of nocturnal asthma, activity limitation,
wheeze 4 times and hospitalization due to acute asthma. Asthma control was classified according to number of fulfilled features;
controlled (0 features), partly controlled (1e2 features) and uncontrolled (3 features).
1236 B. Nordlund et al.Studies regarding severe asthma in the last decade are
difficult to compare due to varying nomenclatures [14].
This stresses the importance of using a global definition e.g.
from the WHO [3]. The first WHO subtype “untreated se-
vere asthma” encompasses patients to whom treatment is
unaffordable, which is not applicable to Swedish condi-
tions, since such treatment is covered by the Swedish social
security system. The second subtype, “difficult-to-treat”,
requires a comprehensive clinical evaluation and is there-
fore not approachable through registers or questionnaires.
Furthermore, this characterization often requires longitu-
dinal clinical assessments and several studies emphasize
visiting a patient’s home environment for proper evaluation
[15,16]. However, we attempted to control adherence and
severity in our definition by including prospective data of
continuously used ICS and LABA. The last WHO subtype,
“treatment-resistant asthma”, includes both uncontrolled
asthma and controlled asthma that can be maintained only
with the highest level of ICS. Asthma control was in our
study based on parental report and we found 3 out of 7
children with controlled asthma and 4 with partly/uncon-
trolled asthma. In line with the WHO definition, these data
suggest that about one in three have controlled “treat-
ment-resistant asthma” and two in three are partly or un-
controlled. In conclusion, severe asthma seems rare both
among schoolchildren with asthma at age 12 and in the
general population. Combining self-reported information
from population-based birth cohorts with data from drug
registers seems trustworthy in estimating severe asthma as
defined by the WHO.Conflict of interest
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